Hengrui Reports Slipped Profit
Jiangsu Hengrui Pharmaceuticals posted a marginal first half profit rise on Wednesday as bulk procurement programs pressured its generics business. Generics revenue dropped while innovative drug sales grew.
Insights:
Jiangsu Hengrui Pharmaceuticals posted a 0.34% rise in first-half net profit on Wednesday afternoon, squeezed by state bulk-buying programs in China. The result marks a slowdown for the country's largest drugmaker by market value as generic drug revenue contracted. Investors are weighing the margin pressure from government healthcare cost controls against the firm's pivot toward innovative treatments.
